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A pedigree-based genetic appraisal of Boxer
ARVC and the role of the Striatin mutation
B. M. Cattanach, J. Dukes-McEwan, P. R. Wotton, H. M. Stephenson, R. M. Hamilton
The objective of this paper was to investigate by pedigree-based genetic means the origins
and inheritance of arrhythmogenic right ventricular cardiomyopathy (ARVC) in UK Boxers and
assess the role of the proposed causal mutation in the gene, Striatin (STRN). All ARVC cases
traced back to a small number of imported American dogs deriving from the group of Boxers
studied by Harpster (1983) to deﬁne the disease, strongly suggesting that the disease is the
same in the two countries. Dogs with and without the STRN mutation were found in both
ARVC affected and normal Boxers showing that the mutation is not responsible for the
disease. Evidence was found that the STRN mutation is, however, genetically linked with the
gene responsible on the same chromosome. The linkage implies that the two genes can
separate by meiotic recombination such that both ARVC-affected and ARVC-unaffected lines
of dogs may carry either the STRN mutation or its wild-type allele. These have been found.
Homozygotes for the STRN mutation tended to be severely affected at early ages, suggesting
that there is an interaction between the known effects of the STRN mutation on the
cardiomyocyte and ARVC.
Introduction
Cardiomyopathy in Boxers is a late-onset familial disease that
has been known in America for at least 30 years. It was ﬁrst
studied in detail by Harpster (1983, 1991) who described three
clinical categories: Cat. 1 showing no clinical signs but having
ventricular arrhythmias, Cat. 2 showing arrhythmias associated
with clinical signs (e.g. syncope), and the most severe, Cat. 3,
showing evidence of congestive heart failure, often biventricular,
with coughing, lethargy and ascites, with or without arrhyth-
mias or syncopal episodes. Cat. 3 shows phenotypic similarities
to canine idiopathic dilated cardiomyopathy (DCM; Harpster
1991). It has not been clearly established whether the severity
categories represent a progression of the disease, or if they have
different aetiologies. The Boxer cardiomyopathy has subse-
quently been well characterised and proposed as a naturally
occurring animal model of the important similar human
condition, arrhythmogenic right ventricular cardiomyopathy
(ARVC), and given this name (Basso and others 2004).
Pedigree analysis has suggested an autosomal dominant
mode of inheritance with incomplete penetrance (Meurs and
others 1999), consistent with human ARVC, but the published
data are limited. A number of different genetic mutations appear
to cause the disease in humans (Iyer and Chin 2013), and the
ﬁnding in ARVC-affected humans of mutations in genes coding
for desmosomal proteins has led to the screening and exclusion
of most of these in Boxers (Meurs and others 2007). However,
one genome-wide association study (GWAS) with subsequent
gene sequencing identiﬁed a deletion mutation in an untrans-
lated region of the Striatin gene (STRN), located on the canis
familiaris chromosome (CFA) 17, which was associated with
Boxer ARVC. This gene was a compelling candidate as the
protein had been shown to localise to the intercalated disc and
co-label with certain desmosomal proteins (Meurs and others
2010). However, 4 of 61 cases investigated by Meurs and others
(2010) did not have the STRN mutation and it was present in
9 of 38 of their controls, the latter attributed to the incomplete
penetrance. Subsequent reports have indicated further exceptions
(Meurs and others 2014, Oxford and others 2014) and anomal-
ous results have been obtained in veterinary practices with the
commercially available ARVC test (e.g. www.laboklin.co.uk/
laboklin/GeneticDiseases.jsp), which is based on the STRN
mutation being the cause of the disease (Dukes-McEwan and
others 2010). The STRN mutation has recently been shown to
be associated with the Cat. 3 phenotype (Meurs and others
2013). The existence of ARVC cases without the STRN geno-
type may indicate genetic heterogeneity, or phenocopies due to
non-genetic causes, or a different genetic cause of Boxer ARVC.
Boxer ARVC was ﬁrst clearly recognised in the UK in the late
1990s (Wotton 1999) and it has been assumed, but not proven,
that the disease is the same as that in the USA. The disease cat-
egories (phenotypes) have commonly been found in UK Boxers
(Palermo and others 2011), some without the STRN mutation
(Dukes-McEwan and others 2010).
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This study does not use experimental protocols, but seeks to
interpret the available breeding and veterinary evidence obtained
from Boxer breeders and practising veterinary surgeons through-
out the UK, with inclusion of like material collected at the
Liverpool and Glasgow veterinary schools. We present pedigree
analyses to (1) show that UK and American Boxer ARVC are the
same, (2) verify that the mode of inheritance is that of an auto-
somal dominant with incomplete penetrance, (3) most import-
antly, we show that the STRN mutation is not the cause of the
disease phenotype but is linked to the responsible gene on the
same chromosome, and (4) illustrate that the three categories of
Boxer ARVC have the same genetic basis but with an STRN
effect possibly interacting to increase severity.
Material and methods
The material for this study comprised UK Boxers with ARVC
together with selected normal dogs collected from the show
section of the breed over the years 2000–2010. Extended pedigree
analyses were conducted by BMC using Kennel Club records.
Blood samples were taken for STRN testing and for other
routine diagnostic testing and surplus blood was stored in EDTA
for genomic DNA extraction and used in an ongoing GWAS
study (R. M. Hamilton, personal communication).
The dogs investigated derived from two sources. ARVC diag-
noses in one group (BMC) were provided by practising veterinary
surgeons’ or veterinary cardiologists’ reports, with diagnoses
(made as below) veriﬁed by review of clinical records by
PRW. The other group, referred directly to Glasgow (PRW) and
Liverpool ( JD-M and HMS) Veterinary Schools, were clinically
diagnosed based on echocardiography, 24 h ambulatory electro-
cardiography (Holter) data (24AECG) according to the criteria
speciﬁed by Meurs (2004), and exclusion of other causes of
arrhythmia. They were then assigned to one of the three
Harpster categories of severity (Harpster 1983, 1991).
For the pedigree studies, veriﬁcation that cases from
both sources speciﬁcally represented inherited disease was estab-
lished by their presence in recognised family groups (BMC).
Relationship was the key criterion for selection of all material for
this genetic study. Rescue dogs and other ARVC cases without
pedigrees were not included. Deduced normal Boxers were
derived from sections of the breed deﬁned by exclusion as free of
the gene causing ARVC (or considered to be at low risk) through
(1) the absence of any reported cases (see Results section) in a
national veterinary screen for Boxer ARVC over the 10-year
period of the study, (2) an absence of deduced ancestral sources
of ARVC in their pedigrees (see Results) and (3) with support for
this conclusion veriﬁed, as possible, by individual dogs in the
study selected as each having several hundred progeny, none of
which have been reported as ARVC cases, this again based on the
national screen. For the veterinary school sources ( JD-M, HMS
and PRW), normal Boxers of ≥8 years old were also phenotyped
(deﬁned as phenotype-normal if unremarkable on echocardiog-
raphy and 24AECG showed <50 VPCs/24 h), but for dogs from
both sources (BMC and veterinary schools), classiﬁcation of
ARVC clear-by-pedigree remained the paramount criterion for
normal (disease gene free or low risk). The mode of inheritance
was ascertained by evaluation of pedigrees over several genera-
tions for evidence of inbreeding or the presence of ARVC-
producing animals on both the sire’s and dam’s pedigrees. Either
ﬁnding might suggest a recessive inheritance, and an absence in
one or other could accord with a dominant. Sexes and severity of
effect were noted to check for possible sex-linked inheritances.
Tracing the origins of the disease was complicated by the fact
that the penetrance was extremely low such that the disease
was rarely recognised in breeding animals. Thus, few parents
were found to be affected even years after producing affected
progeny. Pedigree analysis was therefore conducted by identify-
ing such dogs through their production of affected progeny in
litters with several different mates. Thereafter, lines of descent
were distinguished by tracing these ARVC-producing dogs/
bitches back through the pedigrees until they reached a common
source. Such pedigree analyses were based on 183 ARVC-affected
Boxers from the show section of the breed.
STRN genotyping of the initial Boxers was kindly conducted
by Dr K. Meurs, using an ampliﬁed fragment length polymorph-
ism, as previously described (Meurs and others 2013).
Subsequent samples were genotyped by one of us (RMH) or at
Antagene, courtesy of Dr Anne Thomas. Results were classiﬁed
as being homozygous or heterozygous for the STRN mutation,
or wild type (WT). Evidence on the association between the
mutation and the disease phenotype was sought thereafter.
Statistical methods
The age of diagnosis of ARVC in dogs and bitches was compared
with an unpaired Student t test. Signiﬁcance was accepted as
P<0.05. The genotypes (homozygous and heterozygous for
STRN, WT) were compared between groups with the χ2 test.
Results
General observations
Sexes were near-equally represented (54 per cent males, n=194).
The range of expression as assessed by age of diagnosis was vari-
able (<1 to over 10 years), this range even being found within a
single litter. The median age of diagnosis was seven years. Age of
diagnosis was greater in males than in females but not signiﬁ-
cantly so (P=0.082).
Pedigree studies
The initial observation of ARVC in British Boxers was based on
a cluster of closely inbred cases (Wotton 1999). As further cases
were reported, lines of descent to a few individual ARVC-
producing dogs could be seen (Fig 1, dogs B–F) and ultimately
each of these could be shown to trace back to a single common
ancestor (Fig 1, dog A), mostly through a grandson (Fig 1 dog B).
Together, they are the source of all ARVC in this line of descent
(line 1). Signiﬁcantly, the older dog (A) was derived from
Harpster ’s (1983) ARVC study source in America. Eighty-two
dogs (47 males, 35 females) belonged in line 1.
A second family line of dogs with ARVC was then recognised
(line 2). This also traced back through a series of transmitting dogs
(Fig 2, dogs G–O) to two North American imported males (Fig 2,
dogs G and H), both again linking directly to the group studied by
Harpster (1983). Seventy-six dogs (40 males, 36 females) belonged
in line 2. Some ARVC cases of mixed line 1–line 2 origin were also
found (5 males, 6 females; data not shown).
Finally, a third small family group (line 3) that is now effect-
ively extinct was recognised. This too traced back to the
Harpster study group (data not shown). Twenty-ﬁve dogs
belonged in this line (12 males, 13 females). In that all lines
traced back to a common source, it can be concluded that only
one disease is involved. Importantly, no conﬁrmed ARVC cases
have been reported from outside these three lines over the
10-year span of the study such that the remaining indigenous
population of Boxers in the show section of the breed in the UK
can be deduced to be free of the gene or carry it at a very low fre-
quency with a limited distribution (Fig 3).
Inheritance
Inbreeding is standard procedure in show dog breeding.
Accordingly, inbreeding particularly on one line 1 import (Fig 1,
dog B) initially complicated elucidation of the mode of inherit-
ance, this being further confounded by the low penetrance
which made a skipping of generations virtually the norm.
However, in later line 1 generations, outcrosses to the deduced
normal population also produced the disease, establishing that
ARVC has indeed a single gene autosomal dominant mode of
inheritance as suggested previously (Meurs and others 1999).
This pattern was also evident in line 2. Attempting to estimate
the penetrance was problematical because of the difﬁculty in
monitoring litters over many years. However, indications of very
low penetrance were given by: (1) the observation that transmit-
ting parents were seldom found to develop the disease (Figs 1
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and 2), although checking for disease development in older
animals is uncertain; (2) despite the 50 per cent frequency of
affected animals expected with a dominant gene inheritance,
few litters contained more than a single case manifesting clinical
signs (mean Boxer litter size approximately 6.5) and (3) Holter
conﬁrmation of developing ARVC was prospectively sought
with three aged, symptom-free ARVC-transmitting dogs
(screened at 9, 10 and 13 years, showing evidence of ventricular
arrhythmia with a ‘left bundle-branch block’ morphology and
no other clinical abnormalities), thus conﬁrming their pedigree
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FIG 2: Pedigree chart showing line of descent of dogs transmitting arrhythmogenic right ventricular cardiomyopathy (ARVC) in line 2. Data are
representative of the whole line 2 group (20 per cent of the total) and were selected primarily on the basis of having been STRN tested.
Symbols are the same as in Fig 1. Key ARVC-transmitting dogs are marked G–O. Since the majority of dogs in this line are wild type (WT) for
STRN, it is likely that the original source animals in this line were of this WT genotype. Possible sites of recombination are marked with red
crosses. Only the most informative dogs in terms of age of onset, severity category and STRN genotype are shown
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FIG 1: Pedigree chart showing line of descent of dogs transmitting arrhythmogenic right ventricular cardiomyopathy (ARVC) in line 1. Data are
representative of the whole line 1 group (24 per cent of the total), and were selected primarily on the basis of having been STRN tested.
Squares=males; circles=females; closed symbols=ARVC-affected dogs; shaded symbols=dogs that have produced several cases of ARVC;
HOM=homozygous for the STRN mutation; HET=heterozygous for the STRN mutation; WT=dogs carrying the wild-type alleles of STRN. Key
ARVC-producing dogs are marked A–F. Age of diagnosis is indicated and also ARVC severity category where attainable. Since all affected
cases carry the STRN mutation, it is assumed that the source animal was of this genotype. Only the most informative dogs in terms of age of
onset, severity category and STRN genotype are shown
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genotyping as well as directly illustrating the low penetrance.
The nine-year-old dog had a normal 24AECG initially, but this
was abnormal when retested at 10 years of age. The penetrance
in UK Boxers appears to be far lower than that reported by
Meurs and colleagues (2010), who estimated it to be approxi-
mately 80 per cent in STRN heterozygotes and nearly 100 per
cent in homozygotes. The discordance may reﬂect the different
method of assessment: direct observation on parents of ARVC
cases over many generations in our studies versus numbers of
ARVC-affected dogs as a proportion of a total that expresses
STRN in Meurs and others (2010) data.
STRN disease association
STRN genotyping of dogs in line 1 showed a clear association
between the mutation and the ARVC phenotype (Table 1 and
Fig 1) as described by Meurs and others (2010). Thus, all the
affected dogs were either homozygous or heterozygous for the
STRN mutation. However, by contrast, there was no suggestion
of a STRN disease association in line 2 dogs where WT, as well
as STRN homozygotes (HOM) and heterozygotes (HET), were
found (Fig 2, heterozygotes not shown, Table 1). These data, in
Boxers of close common origin, suggest that the STRN mutation
itself is not the cause of the disease as proposed (Meurs and
others 2010), but provides genetic evidence that a mutation in
another gene lying close to it on the same chromosome is
responsible. Meiotic recombination (Fig 4) can then account for
the observed loose association between the STRN locus and the
ARVC phenotype, with affected dogs being able to be WT,
HOM or HET for the STRN mutation. Support for this is the
indication of an inherited association between the WT allele of
STRN and ARVC in a major section in line 2 (Fig 2) and the
observed switching within line 2 from one association to the
other. We have also conﬁrmed the occurrence of STRN geno-
types HOMs, HETs and WTs in affected and phenotypically
normal dogs (even with an excess of HOMs in the Holter-tested
group) (Table 1; Dukes-McEwan and others 2010), showing that
the STRN mutation does not segregate with the disease status.
Harpster categories of ARVC and age of diagnosis
From Figs 1 and 2 and Table 1, it can be seen that all three esti-
mated categories of ARVC severity can be found within each
line and this makes it very unlikely that the severe Cat. 3 (DCM
phenotype) is a genetically different condition. It can be best
understood as a different expression of the same disease.
However, although age of diagnosis and category were variable,
there was a suggestion of an association between STRN homo-
zygosity and more severe disease, but limited numbers of
assessed dogs precluded further evaluation of this.
Discussion
Most of the information presented here derived from a study on
the incidence and distribution of ARVC in the show section of
the Boxer breed in the UK, which was conducted primarily with
a view to establishing a breeding control scheme for Boxer
owners. Although there is no experimental component to this
study, a number of important conclusions can be drawn concern-
ing aspects of the disease.
Origins
It was possible to trace the origins of the disease in each line by
tracking pedigrees back through transmitting dogs to show that
a small number of breeding animals imported from America
were the source of the disease in the UK and that each of these
originated from, or was closely related to, the group of American
ARVC dogs originally studied by Harpster (1983). It is therefore
highly improbable that different mutations could be responsible
for the disease in the different lines and in the two countries. An
important corollary of this ﬁnding is that the sections of the
breed in the UK that do not have these imported dogs in their
ancestry can be deduced to be free of the gene or are at very low
Indigenous original
population
line 2
line 1
line 3
FIG 3: Diagram depicting the non-random distribution of
arrhythmogenic right ventricular cardiomyopathy (ARVC) throughout
the Boxer breed in the UK. The three family lines at risk of ARVC and
deriving from males imported from the USA are shown, with the
original disease-free section of the breed deﬁned by exclusion
TABLE 1: STRN genotypes observed in Boxer Family line 1,
line 2 and the normal disease-free section of the breed and
comparison with randomly sampled Holter-tested cases and
controls
HOM HET WT Total
Line 1 ARVC cases 10 13 0 23
Line 2 ARVC cases 6 8 10 24
Normal (by pedigree) 5 16 10 31
Holter-tested ARVC cases* 5 14 7 26
Normal (Holter tested)* 6 3 4 13
*Data from Dukes-McEwan and others (2010). Small sample size and different
selection criteria in the two normal groups may account for the differing STRN
mutation frequencies and the Hardy-Weinberg near-disequilibrium in the
Holter-tested normal group (P(null)=0.057). However, there was not a statistically
significant difference between the frequencies of the genotypes in the two
normal groups (P=0.081). The main point is that the STRN mutation is common in
both samples of normal dogs. There is a significant difference between the
frequency of genotypes in lines 1 and 2 (P=0.002). However, there is no
statistically significant difference in the frequency of genotypes between all ARVC
cases and all normals (P=0.0597)
ARVC, arrhythmogenic right ventricular cardiomyopathy; HOM, homozygous for
the STRN deletion mutation; HET, heterozygous for the STRN mutation; WT, wild
type (normal)
STRN STRNARVC
ARVC
+ +
+
+
FIG 4: Diagram depicting recombination between the STRN and the
arrhythmogenic right ventricular cardiomyopathy (ARVC) loci.
Recombination will only be detectable when the transmitting parent
is heterozygous at both STRN and ARVC loci, for example, STRN
ARVC/++ (mutations in coupling), or STRN+/+ ARVC (mutations in
repulsion). Recombination in STRN ARVC/++ parents will yield
STRN+/+ ARVC recombinant progeny, and vice versa, but
recombinants can only be detected when they are homozygous for
an STRN allele, as this is the only way of being sure that the allele in
question is located on the same chromosome as the ARVC mutation
(see Fig 2). For this reason, STRN heterozygotes are not considered
for detecting recombination
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risk. These dogs represent the indigenous population (Fig 3),
which is mostly of Continental European origin, and this is con-
sistent with anecdotal reports from veterinary conferences that
Boxers of Continental breeding are largely free of the disease.
The pedigree analysis is consistent with a single gene homoge-
neous disorder within the Boxer breed and this does not support
the concept that genetic heterogeneity or phenocopies explain
cases of inherited Boxer ARVC that do not carry the STRN
mutation (Meurs and others 2010).
Mode of inheritance and penetrance
On the basis of these ﬁndings, the breeding data show that
affected dogs can inherit the disease from one parent only; a
single gene autosomal dominant inheritance is therefore indi-
cated, as has been suggested by Meurs and others (1999) and
also seen with human ARVC (Iyer and Chin 2013). The pene-
trance cannot be reliably calculated but is indicated to be low
by: (1) the low incidence of the disease in transmitting parents;
(2) the clear shortage of affected progeny among the progeny of
transmitting parents and (3) the detection by Holter of ARVC
among tested older dogs deduced only from their breeding data
to carry the gene. On this basis, the penetrance might appear to
be closer to the 20–30 per cent estimate for ARVC dominant
inheritance in humans (Sen-Chowdhry and others 2005) than
the 80 per cent suggested by Meurs and others (2010).
STRN and ARVC
The most important point indicated by the data presented here
is that the STRN mutation is not responsible for the ARVC.
Thus, although complete association between the mutation and
phenotype was found in line 1 (Fig 1 and Table 1), no such con-
cordance was found in line 2, which has the same recent ances-
tral origin. This line has WTas well as STRN HOMs and HETs
among its numbers, and one section of the family also shows
indications of an inherited WT STRN allele–ARVC association
(Fig 2 and Table 1). Moreover, all three STRN genotypes were
observed among both normal groups (the tested group and the
exclusively deﬁned-by-ancestry group, Table 1). Both of these
normal groups have breeding records that indicate freedom or
low risk of ARVC, the deﬁned-by-ancestry group has served as
an effective control in a GWAS study (R M Hamilton, personal
communication), and ﬁnally both groups are indicated to be
effectively ARVC free by the fact that selective breeding into
this population, which carries the STRN mutation in high fre-
quency, has virtually eliminated ARVC from the show section of
the UK Boxer population. This conclusion is based on both
breeder experience and an absence of ARVC case reports from
those veterinary surgeons who previously reported cases. The
genetic ﬁndings do, however, verify that the disease gene is
located on CFA 17 and that it lies close to STRN such that
meiotic recombination (Fig 4) has been able to generate, and will
continue to generate, WT and STRN genotypes in affected and
unaffected dogs. The pedigree data, not available in Meurs and
others’ (2010) work, provide the genetic evidence for the simple
recombination interpretation and make other complex specula-
tive interpretations, such as genetic heterogeneity, phenocopies
due to non-genetic causes, or two ARVC loci on the same
chromosome, highly unlikely. It should also be noted that to
enable recognition of meiotic recombination, the hypothesis
requires that the STRN mutation is segregating in the normal
Boxer population, British and American. This has been veriﬁed
in the UK (Dukes-McEwan and others 2010) and is also indi-
cated in the deﬁned-by-ancestry disease-free section of the breed
employed in the present study (Table 1).
While this STRN conclusion is at variance with that of
Meurs and others (2010), it is not at variance with their ﬁndings.
They noted that 4/61 affected dogs did not have the mutation
and 9/38 normal controls did (attributed to low penetrance),
and recently, Meurs and others (2014) have also reported that
7/43 genotyped Boxers diagnosed with ARVC were negative for
the STRN mutation (16 per cent). In addition, they identiﬁed
the STRN locus in the smaller of two statistically signiﬁcant
GWAS peaks 4 Mb apart on CFA 17. In view of the STRN–
ARVC causal locus recombination indicated here, it is likely that
the larger peak encompasses the gene for ARVC despite the per-
ceived absence of deﬁned genes in this region (Meurs and others
2010). The data of Meurs and others (2010) and the pedigree
data presented here both indicate that further scans for this
second CFA 17 locus should be instigated.
The consequences
The ﬁnding that the STRN mutation is not responsible for
ARVC means that ARVC-affected dogs without the mutation
are not being recognised as having the inherited ARVC, and
many normal dogs with the mutation are erroneously being
deﬁned as carrying the disease. A further outcome from the con-
clusions is that homozygosity for the STRN mutation no longer
indicates homozygosity for the actual ARVC mutation. The fate
of these ARVC homozygotes is now unclear. However, STRN
remains a loose marker for the ARVC gene and still identiﬁes the
gross region. It should therefore be possible to ﬁnd DNA markers
that are closer to the ARVC gene and that could therefore serve
better for identifying dogs that carry it. Such an exercise might
also help the detection of the gene itself, in humans as well as
Boxers.
A possible STRN effect
Our previous studies have shown that the age of diagnosis in
homozygotes for the STRN mutation may be earlier than those
with other STRN genotypes, although the difference was not
statistically signiﬁcant (Dukes-McEwan and others 2010). The
trend can be visualised more explicitly in the pedigree charts pre-
sented here (Figs 1 and 2), with STRN HOM–WT comparisons
being possible in line 2. For some of these dogs, Harpster severity
categories have also been determined and a further association
between these and the age of diagnosis is suggested Indeed,
Meurs described the frequency of ventricular ectopy (Meurs and
others 2010) and the DCM phenotype (Meurs and others 2013)
to be associated with the STRN mutation, and possibly with
homozygosity, and this equally accords with the ARVC locus
being close to STRN. Although an age-based progression of the
disease possibly confuses severity assignments, examples of
late-onset Cat. 1 cases can be found and these are consistent
with the low genetic penetrance of the disease. Progression is
recognised with the more severe Cat. 2 and 3 cases. As STRN
plays a role in the cardiomyocyte, it may interact with the
(unknown) ARVC mutation to trigger its development, as may
exercise, myocarditis, stress or concurrent heart conditions.
Furthermore, the STRN genotype may inﬂuence the severity or
manifestation of other cardiac diseases.
Limitations of this study
As with any mainly retrospective clinical study, there are poten-
tial limitations with this work. ARVC is not an easy disease to
diagnose, and the guidelines for diagnosis in humans include
consideration of the family history alongside imaging and ECG
(Smith and others 2011). Only a proportion of our controls (free
of ARVC disease or gene) were conﬁrmed to be free of the
disease by active phenotyping (echo, 24AECG), the others being
deduced to be free by pedigree analysis (through having no evi-
dence of disease in ancestors or offspring over many genera-
tions). However, although this might appear to be a source of
inaccuracy, with a low penetrance, late-onset familial disease
such as ARVC in Boxers, the pedigree-led approach is potentially
more reliable than conventional clinical screening. An individual
carrying the gene would be expected to show evidence of this
somewhere in their ancestry or offspring if a sufﬁciently wide
time span is considered, whereas they might appear to be com-
pletely normal when examined by ECG and 24AECG on only
one or two occasions. Over-reliance on clinical screening, ignor-
ing familial history, could easily have resulted in animals carry-
ing the gene being erroneously included as controls in previous
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studies. The pedigree-led approach was further validated as it
allowed the identiﬁcation and targeted screening of some ‘dis-
cordant’ dogs, apparently healthy but known to transmit ARVC
to their progeny, conﬁrming the presence of Cat. 1 ARVC
(asymptomatic ventricular arrhythmias with no other explan-
ation) in these individuals.
Ventricular arrhythmias can be the result of other cardiac dis-
eases and systemic conditions, which ideally should be excluded (e.
g. by blood tests, abdominal and cardiac ultrasonography) before a
diagnosis of ARVC is made. The ARVC cases were phenotyped as
fully as possible, particularly the cases referred to the Liverpool and
Glasgow Veterinary Hospitals. The BMC group of cases were seen
by various different clinicians and cardiologists, but one author
(PRW) reviewed all diagnoses for this group of ARVC cases, and
where the diagnosis was in doubt that case was excluded. Only
potential ARVC cases with a veriﬁable pedigree were included.
Independent of any of the aforementioned concerns about
accurate phenotyping, the main conclusion of this study, namely
that the STRN mutation is not the cause of ARVC in Boxers, is
established from the observation of inherited WTARVC lines of
dogs within line 2, in addition to those carrying the STRN
mutation. Clinically normal dogs carrying the STRN mutation
have been found in all published Boxer ARVC studies using
24AECG testing (Dukes-McEwan and others 2010, Meurs and
others 2014, Oxford and others 2014) as well as in the original
work (Meurs and others 2010). Their presence was explained in
these publications by incomplete penetrance, but here we
suggest the presence of a separate, though linked, gene. With
meiotic recombination between the STRN and a true ARVC
locus on CFA 17, all STRN genotypes should be found in
affected and normal Boxers, which is the case. Incomplete pene-
trance of the ARVC mutation is only an additional factor, and
direct evidence for this is provided in this study.
Conclusions
Pedigree studies indicate that Boxer ARVC in the UK has the same
genetic basis as that in the USA. It appears to be caused by a single
dominant gene mutation with incomplete penetrance located on
CFA 17, but this is not the candidate gene STRN, the observed
mutation of which can be present or absent within families of
ARVC dogs, and is widely present in disease-free sections of the
breed. Instead, STRN appears to serve only as a linked marker for
an as yet undetected ARVC locus lying on the same chromosome
and thus tends to be co-inherited with it, but the STRN–ARVC
association is broken when there is meiotic recombination
between the two genes. The severity categories and varying ages
of diagnosis are indicated to be varying expressions of the one
disease rather than attributable to different cardiomyopathies.
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